EUVIMEDEUVIMED entdecken
Crossref

Vonoprazan (Voquezna) for Nonerosive GERD

The Medical Letter on Drugs and Therapeutics · 2024

DOI: 10.58347/tml.2024.1713c ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Medical Letter on Drugs and Therapeutics, 2024. Hauptthemen laut MEDLINE: Gastroesophageal Reflux, Sulfonamides, Proton Pump Inhibitors, Pyrroles.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The potassium-competitive acid blocker vonoprazan (Voquezna – Phathom), which was approved earlier for treatment of erosive esophagitis, has now been approved by the FDA for relief of heartburn associated with nonerosive gastroesophageal reflux disease (GERD) in adults.1 Vonoprazan is also available copackaged with amoxicillin (Voquezna Dual Pak) and with amoxicillin and clarithromycin (Voquezna Triple Pak) for treatment of Helicobacter pylori infection.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Gastroesophageal RefluxSulfonamidesProton Pump InhibitorsPyrrolesHumansDrug InteractionsTreatment Outcome

Stichwörter der Autor:innen

Clostridioides difficileGERDH2 receptor antagonistsHelicobacter pylori infectionPPIsVoqueznaadverse effectsamoxicillinclarithromycindosagedrug interactionsefficacylactationpregnancysafety

Substanzen

1-(5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl)-N-methylmethanamineSulfonamidesProton Pump InhibitorsPyrroles

Zitieren

APA

(2024). Vonoprazan (Voquezna) for Nonerosive GERD. The Medical Letter on Drugs and Therapeutics. https://doi.org/10.58347/tml.2024.1713c

Vancouver

Vonoprazan (Voquezna) for Nonerosive GERD. The Medical Letter on Drugs and Therapeutics. 2024. doi:10.58347/tml.2024.1713c

BibTeX
@article{euvimed2024,
  title = {Vonoprazan (Voquezna) for Nonerosive GERD},
  journal = {The Medical Letter on Drugs and Therapeutics},
  year = {2024},
  doi = {10.58347/tml.2024.1713c}
}
Kostenlos starten →